and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by reference in such a filing.

Entry into a Material Definitive Agreement. Agreement and Plan of Merger On July 1, 2026, Vivani Medical, Inc. (“Vivani”) entered into a definitive agreement and plan of merger (the “Merger Agreement”) among its wholly owned subsidiary Cortigent, Inc. (“Cortigent”), ClearOne, Inc. (“ClearOne”), a Nasdaq-listed Nevada company, and CLRO Merger Sub, Inc. a Delaware corporation wholly owned subsidiary of ClearOne (“MergerSub”), pursuant to which Cortigent will merge with and into MergerSub (the “…

The filing describes an amendment and restatement of the company's incentive plan, which is not a management change event.

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by reference in such a filing.

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by reference in such a filing.

Entry into a Material Definitive Agreement. Private Placement Vivani Medical, Inc. (the “Company”) entered into a Share Purchase Agreement, dated January 25 , 2026 (the “Purchase Agreement”), with an entity affiliated with Gregg Williams, Chairman of the Company’s board of directors (the “Purchaser”) for the purchase of an aggregate of 1,351,351 shares of common stock, par value of $0.0001 per share (“Common Stock”) of the Company at a purchase price of $1. 4 8 per share (the “Private Placeme…

in its entirety, the Company has agreed to sell the Private Placement Shares to “accredited investors,” as that term is defined in the Securities Act, in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act and corresponding provisions of state securities or “blue sky” laws. The Purchaser represented that they are acquiring the Shares for investment only and not with a view towards, or f…

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by reference in such a filing.

Entry into a Material Definitive Agreement. Private Placement Vivani Medical, Inc. (the “Company”) entered into a Share Purchase Agreement, dated October 2 6 , 2025 (the “Purchase Agreement”), with an entity affiliated with Gregg Williams, Chairman of the Company’s board of directors (the “Purchaser”) for the purchase of an aggregate of 3,703,703 shares of common stock , par value of $0.0001 per share (“Common Stock”) of the Company at a purchase price of $ 1.62 per share (the “ Private Place…

in its entirety, the Company has agreed to sell the Private Placement Shares to “accredited investors,” as that term is defined in the Securities Act, in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act and corresponding provisions of state securities or “blue sky” laws. The Purchaser represented that they are acquiring the Shares for investment only and not with a view towards, or f…

Other Events. Withdrawal of Record Date for Cortigent Spin-off On October 3, 2025, the Company announced that it is temporarily withdrawing the previously-announced record date of October 8, 2025 for the proposed spinoff of its wholly-owned subsidiary, Cortigent, Inc., which is developing brain implant devices with cutting-edge neuromodulation technology, due to delays arising from the current shutdown of the U.S. federal government.

Other Events. Record Date for Cortigent Spin-off On September 17, 2025, Vivani Medical, Inc. (the “Company”) announced that the record date for the previously announced spin-off of Cortigent, Inc. (“Cortigent”), the Company’s wholly-owned subsidiary, is set for October 8, 2025 (the “Record Date”). Cortigent is developing brain implant devices with neuromodulation technology. The Company’s stockholders holding common stock of the Company as of the Record Date will receive common stock in Corti…

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by reference in such a filing.

Other Events. On August 13, 2025, the Company issued a press release titled “ Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results ,” which included information relating to the private placement described in

Entry into a Material Definitive Agreement. Vivani Medical, Inc. (the “Company”) entered into a Share Purchase Agreement, effective August 11, 2025 (the “Purchase Agreement”), with an entity affiliated with one of its directors and another investor listed in the Purchase Agreement (collectively, the “Purchasers”) for the purchase of an aggregate of 7,936,507 shares of common stock of the Company priced at $1.26 per share (the “Shares”), the last reported sale price of the common stock on Augu…

in its entirety, the Company has agreed to sell the Shares to “accredited investors,” as that term is defined in the Securities Act, in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act and corresponding provisions of state securities or “blue sky” laws. The investors represented that they are acquiring the Shares for investment only and not with a view towards, or for, resale in conn…

is incorporated herein by reference. LIBERATE-1 Clinical Data Press Release On August 5, 2025, the Company issued a press release to report results from the LIBERATE-1 clinical study, the Phase 1 study of the exenatide GLP-1 implant NPM-115 representing the first-in-human test of the Company’s proprietary NanoPortal™ implant technology. The Company also reported new feasibility data for NPM-139 (semaglutide implant) from an ongoing preclinical study, supporting prioritization of the semagluti…

Chief Financial Officer — Brigid Makes: Brigid Makes resigned from her role as Chief Financial Officer.

Other Events. On May 29 , 2025, Vivani Medical, Inc. (the “Company”) issued a press release titled “ Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders ” in relation to Cortigent , Inc. (“ Cortigent ”), a wholly owned subsidiary of the Company, filing a Form 10 registration statement with the U.S. Securities and Exchange Commission such that Cortigent will become an independent, publicly traded c…

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by reference in such a filing.

in its entirety, the Company has agreed to sell the Shares to an “accredited investor,” as that term is defined in the Securities Act, in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act and corresponding provisions of state securities or “blue sky” laws. The investor represented that he is acquiring the Shares for investment only and not with a view towards, or for, resale in connec…

Other Events. On May 13, 2025, the Company issued a press release titled “ Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results ,” which included information relating to the private placement described in

Entry into a Material Definitive Agreement. Vivani Medical, Inc. (the “Company”) entered into a Share Purchase Agreement, effective May 12, 2025, with an entity beneficially owned by Gregg Williams, Chairman of the Board of Directors of the Company (the “Purchaser”) for the purchase of an aggregate of 2,912,621 shares of common stock of the Company priced at $1.03 per share (the “Shares”), the last reported sale price of the common stock on the effective date. This placement of common stock i…

Other Events. On April 12, 2025, Vivani Medical, Inc. (the “Company”) entered into an amendment to that certain License and Supply Agreement with Okava Pharmaceuticals, Inc. (“Okava”) to expand the Company’s ongoing collaboration with Okava to include dogs in the development of OKV-119, a long-acting GLP-1 therapy for weight management, diabetes and other cardiometabolic conditions (the “Okava Collaboration”). On April 15, 2025, the Company and Okava jointly issued a press release titled “ Vi…

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by reference in such a filing.